<SEC-DOCUMENT>0001415889-24-025671.txt : 20241028
<SEC-HEADER>0001415889-24-025671.hdr.sgml : 20241028
<ACCEPTANCE-DATETIME>20241028161150
ACCESSION NUMBER:		0001415889-24-025671
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20241018
FILED AS OF DATE:		20241028
DATE AS OF CHANGE:		20241028

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Davis Gregory D
		CENTRAL INDEX KEY:			0002041855
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		241401004

	MAIL ADDRESS:	
		STREET 1:		C/O SANGAMO THERAPEUTICS, INC.
		STREET 2:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3-10282024_081047.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2024-10-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001001233</issuerCik>
        <issuerName>SANGAMO THERAPEUTICS, INC</issuerName>
        <issuerTradingSymbol>SGMO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002041855</rptOwnerCik>
            <rptOwnerName>Davis Gregory D</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SANGAMO THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>501 CANAL BLVD.</rptOwnerStreet2>
            <rptOwnerCity>RICHMOND</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94804</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Head of Research &amp; Technology</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>203089</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>9.16</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-06-25</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>60000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>11.19</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-02-25</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>25000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.9</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-02-25</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>27225</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.66</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-02-24</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>64688</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">1.	Includes (a) 2,836 shares subject to the Reporting Person's February 25, 2022 restricted stock unit (&quot;RSU&quot;) grant that will vest in successive equal quarterly installments through February 25, 2025, (b) 12,129 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the &quot;2018 EIP&quot;)) through each such date and subject to acceleration as provided in the 2018 EIP.</footnote>
        <footnote id="F2">Fully vested and exercisable.</footnote>
        <footnote id="F3">One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2021 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.</footnote>
        <footnote id="F4">One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2022 grant date, and the remainder of the shares subject to the option vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.</footnote>
        <footnote id="F5">One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 24, 2023 grant date, and the remainder of the shares subject to the option will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Ron A. Metzger, Attorney-in-Fact</signatureName>
        <signatureDate>2024-10-28</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ex24-10282024_081051.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex24-10282024_081051.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin-top:0px; margin-bottom:13.467px; font-size:11pt" align="center"><b>POWER OF ATTORNEY</b></p>
<p style="margin-top:0px; margin-bottom:13.467px; text-indent:48px; font-size:11pt" align="justify">Know all by these presents, that the undersigned hereby constitutes and appoints Prathyusha Duraibabu, Scott Willoughby, Nikunj Jain, Frances Tan and Ron A. Metzger of Cooley LLP, counsel to Sangamo Therapeutics, Inc. (the <font style="font-family:Arial Unicode MS,Times New Roman">&ldquo;</font><b><i>Company</i></b><font style="font-family:Arial Unicode MS,Times New Roman">&rdquo;</font>), with full power of substitution, the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s true and lawful attorney-in-fact to:</p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:24px; width:48px; font-size:12pt; float:left">1.</p>
<p style="margin-top:0px; margin-bottom:13.467px; padding-left:48px; text-indent:-2px; font-size:11pt" align="justify">execute for and on behalf of the undersigned, in the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s capacity as an officer or director, as the case may be, of the Company, Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the <font style="font-family:Arial Unicode MS,Times New Roman">&ldquo;</font><b><i>Exchange Act</i></b><font style="font-family:Arial Unicode MS,Times New Roman">&rdquo;</font>), and the rules thereunder;</p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:24px; width:48px; font-size:12pt; clear:left; float:left">2.</p>
<p style="margin-top:0px; margin-bottom:13.467px; padding-left:48px; text-indent:-2px; font-size:11pt" align="justify">do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the <font style="font-family:Arial Unicode MS,Times New Roman">&ldquo;</font><b><i>SEC</i></b><font style="font-family:Arial Unicode MS,Times New Roman">&rdquo;</font>) and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC;</p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:24px; width:48px; font-size:12pt; clear:left; float:left">3.</p>
<p style="margin-top:0px; margin-bottom:13.467px; padding-left:48px; text-indent:-2px; font-size:11pt" align="justify">seek or obtain, as the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s representative and on the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s behalf, information on transactions in the Company<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s securities from any broker or financial institution, and the undersigned hereby authorizes any such person to release any such information to each of the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s attorneys-in-fact appointed by this Power of Attorney and approves and ratifies any such release of information; and</p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:24px; width:48px; font-size:12pt; clear:left; float:left">4.</p>
<p style="margin-top:0px; margin-bottom:13.467px; padding-left:48px; text-indent:-2px; font-size:11pt" align="justify">take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s discretion.</p>
<p style="margin-top:0px; margin-bottom:13.467px; text-indent:48px; font-size:11pt; clear:left" align="justify">The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.</p>
<p style="margin-top:0px; margin-bottom:13.467px; text-indent:48px; font-size:11pt" align="justify">The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.</p>
<p style="margin-top:0px; margin-bottom:13.467px; text-indent:48px; font-size:11pt" align="justify">This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.</p>
<p style="margin-top:0px; margin-bottom:13.467px; text-indent:48px; font-size:11pt" align="justify">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on 10/15/24.</p>
<p style="margin-top:0px; margin-bottom:13.467px; font-size:11pt" align="justify">Signature:</p>
<p style="margin:0px" align="justify"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="margin:0px; font-size:11pt; page-break-before:always" align="justify"><u>/s/ Gregory D. Davis</u></p>
<p style="margin-top:0px; margin-bottom:13.467px; font-size:11pt" align="justify">Gregory D. Davis</p>
<p style="margin-top:0px; margin-bottom:14.667px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:14.667px" align="justify"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
